Inverse regulation of DHT synthesis enzymes 5α-reductase types 1 and 2 by the androgen receptor in prostate cancer

37Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

5α-Reductase types 1 and 2, encoded by SRD5A1 and SRD5A2, are the two enzymes that can catalyze the conversion of testosterone to dihydrotestosterone, the most potent androgen receptor (AR) agonist in prostate cells. 5a-Reductase type 2 is the predominant isoform expressed in the normal prostate. However, its expression decreases during prostate cancer (PCa) progression, whereas SRD5A1 increases, and the mechanism underlying this transcriptional regulatory switch is still unknown. Interrogation of SRD5A messenger RNA expression in three publicly available data sets confirmed that SRD5A1 is increased in primary and metastatic PCa compared with nontumoral prostate tissues, whereas SRD5A2 is decreased. Activation of AR, a major oncogenic driver of PCa, induced the expression of SRD5A1 from twofold to fourfold in three androgen-responsive PCa cell lines. In contrast, AR repressed SRD5A2 expression in this context. Chromatin-immunoprecipitation studies established that AR is recruited to both SRD5A1 and SRD5A2 genes following androgen stimulation but initiates transcriptional activation only at SRD5A1 as monitored by recruitment of RNA polymerase II and the presence of the H3K27Ac histone mark. Furthermore, we showed that the antiandrogens bicalutamide and enzalutamide block the AR-mediated regulation of both SRD5A1 and SRD5A2, highlighting an additional mechanism explaining their beneficial effects in patients. In summary, we identified an AR-dependent transcriptional regulation that explains the differential expression of 5a-reductase types 1 and 2 during PCa progression. Our work thus defines a mechanism by which androgens control their own synthesis via differential regulatory control of the expression of SRD5A1 and SRD5A2.

References Powered by Scopus

The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data

12397Citations
N/AReaders
Get full text

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

11199Citations
N/AReaders
Get full text

Integrative Genomic Profiling of Human Prostate Cancer

3036Citations
N/AReaders
Get full text

Cited by Powered by Scopus

SREBF1 activity is regulated by an AR/mTOR nuclear axis in prostate cancer

60Citations
N/AReaders
Get full text

A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to profile 20 plasma steroids in endocrine disorders

48Citations
N/AReaders
Get full text

Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer

43Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Audet-Walsh, É., Yee, T., Tam, I. S., & Giguère, V. (2017). Inverse regulation of DHT synthesis enzymes 5α-reductase types 1 and 2 by the androgen receptor in prostate cancer. Endocrinology, 158(4), 1015–1021. https://doi.org/10.1210/en.2016-1926

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 14

74%

Professor / Associate Prof. 2

11%

Researcher 2

11%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 10

43%

Medicine and Dentistry 6

26%

Pharmacology, Toxicology and Pharmaceut... 5

22%

Agricultural and Biological Sciences 2

9%

Save time finding and organizing research with Mendeley

Sign up for free